摘要
目的研究阿格列汀、二甲双胍对2型糖尿病患者的疗效及IL-18、SAA的影响。方法选取2015年1月—2017年12月我院收治的80例2型糖尿病患者作为研究对象,将其随机均分对照组组(40例)与观察组(40例)。分析阿格列汀、二甲双胍治疗价值。结果治疗后,观察组FBG、2 h PG、Hb Alc水平均较对照组低,并恢复正常,SAA、IL-18水平均较对照组低,两组对比,差异有统计学意义(P<0.05)。结论阿格列汀对2型糖尿病患者血糖控制具有较好的效果,能显著降低IL-18、SAA水平,有利于患者康复。
Objective To study the effect of alogliptin and metformin on type 2 diabetes mellitus and the effect of IL-18 and SAA. Methods From January 2015 to December 2017, 80 patients with type 2 diabetes in our hospital were selected as the research subjects. They were randomly divided into metformin group（40 cases） and alogliptin group（40 cases）. To analyze the value of alogliptin and metformin in the treatment of metformin. Results After treatment, the levels of FBG, 2 h PG and Hb Alc in the observation group were lower than those in the control group and recovered to normal. The levels of SAA and IL-18 were lower than those of the control group, and the difference between the two groups was statistically significant（P〈0.05）. ConclusionAlogliptin has a good effect on blood glucose control in patients with type 2 diabetes mellitus, which can significantly reduce the level of IL-18 and SAA, and is conducive to the rehabilitation of patients.
作者
郑志刚
于敏
唐平
陈巧红
ZHENG Zhigang;YU Min;TANG Ping;CHEN Qiaohong(Department of Internal Medicine,The People＇s Hospital of Yantian District,Shenzhen Guangdong 518083,China)
出处
《中国继续医学教育》
2018年第18期132-134,共3页
China Continuing Medical Education
基金
深圳市科技计划项目(课题名称:阿格列汀
二甲双胍对2型糖尿病患者的疗效及IL-18
SAA的影响
课题编号:JCYJ20150403111252444)
